Pd Knowledge Gaps Ranked is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Task ID: pd002
Created: 2026-03-06
Slot: 5 (Mechanistic Models)
Status: P0
This page identifies and ranks the top 20 unanswered questions in Parkinson's Disease (PD) research. Each gap is scored on four dimensions:
- Impact if solved (0-10): Would solving this gap change treatment?
- Tractability (0-10): Is this answerable with current technology?
- Current effort (0-10, inverted): Are too few people working on this? (High score = underexplored)
- Data availability (0-10): Do we have the datasets/biobanks/models to study this?
Total: 40 points max per gap.
| Rank |
Knowledge Gap |
Impact if Solved |
Tractability |
Current Effort |
Data Availability |
Total |
| 1 |
What triggers alpha-synuclein aggregation in sporadic PD? |
10 |
6 |
7 |
7 |
30 |
| 2 |
What causes selective vulnerability of dopaminergic neurons in the substantia nigra? |
10 |
7 |
6 |
7 |
30 |
| 3 |
Why do some LRRK2/GBA mutation carriers never develop PD? |
9 |
7 |
8 |
6 |
30 |
| 4 |
What is the role of the gut-brain axis in PD pathogenesis? |
9 |
7 |
7 |
7 |
30 |
| 5 |
Is PD one disease or several distinct syndromes with shared symptoms? |
10 |
5 |
7 |
6 |
28 |
| 6 |
Does alpha-synuclein spreading cause neurodegeneration or is it a bystander? |
10 |
6 |
6 |
7 |
29 |
| 7 |
What is the relationship between REM sleep behavior disorder (RBD) and PD? |
9 |
8 |
5 |
8 |
30 |
| 8 |
Why do women get PD less than men (2:1 male:female ratio)? |
8 |
6 |
8 |
6 |
28 |
| 9 |
What is the role of viral infections (EBV, HSV-1, HHV-6) in PD? |
8 |
6 |
7 |
6 |
27 |
| 10 |
What are the mechanisms of non-motor symptom progression (cognitive, autonomic)? |
9 |
6 |
6 |
7 |
28 |
| 11 |
Can we develop reliable prodromal biomarkers for early detection? |
9 |
7 |
5 |
7 |
28 |
| 12 |
What determines why some patients develop tremor-dominant vs PIGD phenotype? |
7 |
6 |
8 |
6 |
27 |
| 13 |
What is the role of mitochondrial DNA mutations in sporadic PD? |
7 |
6 |
7 |
6 |
26 |
| 14 |
How does the microbiome affect drug metabolism in PD patients? |
7 |
6 |
7 |
7 |
27 |
| 15 |
What causes levodopa-induced dyskinesias and how can they be prevented? |
9 |
7 |
4 |
7 |
27 |
| 16 |
What is the role of neuroinflammation vs alpha-synuclein in driving disease? |
9 |
6 |
5 |
6 |
26 |
| 17 |
Can we develop disease-modifying therapies targeting LRRK2? |
8 |
7 |
5 |
6 |
26 |
| 18 |
What is the optimal timing for intervention (pre-motor vs early motor)? |
9 |
6 |
5 |
5 |
25 |
| 19 |
How do environmental exposures (pesticides, metals) interact with genetic risk? |
8 |
5 |
7 |
5 |
25 |
| 20 |
What determines individual response variability to dopaminergic therapies? |
7 |
6 |
6 |
7 |
26 |
- Why it matters: Alpha-synuclein aggregation is the hallmark pathology in >95% of PD cases, but we don't know what initiates the process in patients without genetic mutations.
- Current evidence: Mutations (SNCA duplication, A53T) cause rare familial cases; however, 90% of PD is sporadic with unknown triggers.
- Research needed: Identify environmental triggers, post-translational modifications, or cellular stress pathways that initiate aggregation.
- Key references:
- Why it matters: Understanding why SNpc neurons die while VTA neurons are relatively spared could reveal protective pathways.
- Current evidence: Multiple factors implicated: high metabolic demand, calcium dysregulation, iron accumulation, neuromelanin, autonomous pacemaking.
- Research needed: Single-cell RNA-seq of surviving vs dying neurons; comparative studies of resistant populations.
- Key references:
- Surmeier DJ, et al. (2017). Selective vulnerability of dopaminergic neurons. Nat Rev Neurosci. DOI:10.1038/nrn.2017.49
- Why it matters: These individuals carry known genetic risk factors but remain disease-free, suggesting protective mechanisms.
- Current evidence: ~30% of LRRK2 G2019S carriers develop PD by age 80; similar penetrance for GBA variants.
- Research needed: Whole-genome sequencing to identify protective variants; longitudinal biomarker studies.
- Key references:
- Why it matters: GI symptoms often precede motor symptoms by years; alpha-synuclein aggregates found in enteric nervous system.
- Current evidence: Braak hypothesis suggests pathology may start in gut and propagate via vagus nerve.
- Research needed: Interventional studies targeting gut (microbiome transplantation, antibiotics); understand propagation mechanism.
- Key references:
- Braak H, et al. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. DOI:10.1016/s0197-4580(0200065-9
- Why it matters: Would inform precision medicine approaches and clinical trial design.
- Current evidence: Clinical heterogeneity is well-documented (tremor-dominant vs PIGD, cognitive impairment vs preserved).
- Research needed: Subtype-specific biomarker development; targeted therapeutic approaches.
- Key references:
%%{init: {'theme': 'base', 'themeVariables': {'primaryColor': '#FF9800'}}}%%
graph TD
A[Alpha-Syn Aggregation] --> B[Selective Vulnerability] -->
A --> C[Gut-Brain Axis)
C --> D[PD Subtypes] -->
B --> D
E[Genetic Carriers Protected] --> C
E --> B
F[RBD Prodrome] --> D
G[Non-Motor Progression] --> D
H[Sex Differences] --> D
style A fill:#f44336,stroke:#333
style B fill:#f44336,stroke:#333
style C fill:#ff9800,stroke:#333
style D fill:#ff9800,stroke:#333
style E fill:#ffc107,stroke:#333
style F fill:#ffc107,stroke:#333
style G fill:#ffc107,stroke:#333
style H fill:#ffc107,stroke:#333
- What triggers alpha-synuclein aggregation? (Rank 1)
- Role of gut-brain axis (Rank 4)
- Viral infections in PD (Rank 9)
- Environmental-genetic interactions (Rank 19)
- Selective vulnerability (Rank 2)
- Alpha-synuclein spreading (Rank 6)
- Neuroinflammation vs proteinopathy (Rank 16)
- Mitochondrial DNA role (Rank 13)
- RBD relationship (Rank 7)
- Non-motor progression (Rank 10)
- Prodromal biomarkers (Rank 11)
- Phenotype determinants (Rank 12)
- LRRK2 therapy development (Rank 17)
- Optimal intervention timing (Rank 18)
- Levodopa-induced dyskinesias (Rank 15)
- Response variability (Rank 20)
- Sex differences (Rank 8)
- Disease subtypes (Rank 5)
- Study LRRK2 non-manifesting carriers - natural experiment in protection
- RBD follow-up studies - well-defined prodromal population
- Single-cell analysis of SNpc - emerging technology
- Gut-brain axis intervention - requires long-term studies
- Alpha-synuclein trigger identification - needs novel assays
- Sex differences research
- Environmental exposure interactions
- Microbiome-drug interactions
The study of Pd Knowledge Gaps Ranked has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Surmeier DJ, et al. (2017). Selective vulnerability of dopaminergic neurons. Nat Rev Neurosci. DOI:10.1038/nrn.2017.49
- Braak H, et al. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. DOI:10.1016/s0197-4580(0200065-9
- Kalia LV, Lang AE. (2015). Parkinson's disease. Lancet. DOI:10.1016/S0140-6736(1461393-3
- Heutink P, et al. (2022). LRRK2 penetrance. Nat Rev Neurol. DOI:10.1038/s41582-022-00645-6
- Spillantini MG, et al. (1997). alpha-Synuclein in Lewy bodies. Nature. DOI:10.1038/42166
- Singleton AB, et al. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science. DOI:10.1126/science.1086162
- Lewis SJ, et al. (2005). Heterogeneity of Parkinson's disease. Brain. DOI:10.1093/brain/awh399
- Poewe W, et al. (2017). Parkinson disease. Nat Rev Dis Primers. DOI:10.1038/nrdp.2017.13
- Berg D, et al. (2021). Prodromal Parkinson's disease. Nat Rev Neurol. DOI:10.1038/s41582-021-00486-9
- Schapira AHV, et al. (2019). Novel pharmacological targets for Parkinson disease. Nat Rev Neurol. DOI:10.1038/s41582-019-0241-0
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 36%